Literature DB >> 11052954

Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production.

D V Chirieac1, L R Chirieac, J P Corsetti, J Cianci, C E Sparks, J D Sparks.   

Abstract

The current study assessed in vivo the effect of insulin on triglyceride-rich lipoprotein (TRL) production by rat liver. Hepatic triglyceride and apolipoprotein B (apoB) production were measured in anesthetized, fasted rats injected intravenously with Triton WR-1339 (400 mg/kg). After intravascular catabolism was blocked by detergent treatment, glucose (500 mg/kg) was injected to elicit insulin secretion, and serum triglyceride and apoB accumulation were monitored over the next 3 h. In glucose-injected rats, triglyceride secretion averaged 22.5 +/- 2.1 microg.ml(-1).min(-1), which was significantly less by 30% than that observed in saline-injected rats, which averaged 32.1 +/- 1.4 microg.ml(-1).min(-1). ApoB secretion was also significantly reduced by 66% in glucose-injected rats. ApoB immunoblotting indicated that both B100 and B48 production were significantly reduced after glucose injection. Results support the conclusion that insulin acts in vivo to suppress hepatic very low density lipoprotein (VLDL) triglyceride and apoB secretion and strengthen the concept of a regulatory role for insulin in VLDL metabolism postprandially.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11052954     DOI: 10.1152/ajpendo.2000.279.5.E1003

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  25 in total

1.  Differential vasomotor effects of insulin on gastrocnemius and soleus feed arteries in the OLETF rat model: role of endothelin-1.

Authors:  Nathan T Jenkins; Jaume Padilla; Jeffrey S Martin; Jacqueline M Crissey; John P Thyfault; R Scott Rector; M Harold Laughlin
Journal:  Exp Physiol       Date:  2013-08-30       Impact factor: 2.969

Review 2.  Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome.

Authors:  Paul D Berk
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

Review 3.  Can modulators of apolipoproteinB biogenesis serve as an alternate target for cholesterol-lowering drugs?

Authors:  Lynley M Doonan; Edward A Fisher; Jeffrey L Brodsky
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-04-06       Impact factor: 4.698

4.  Acute suppression of apo B secretion by insulin occurs independently of MTP.

Authors:  Janet D Sparks; Jeffrey M Chamberlain; Colleen O'Dell; Irani Khatun; M Mahmood Hussain; Charles E Sparks
Journal:  Biochem Biophys Res Commun       Date:  2011-02-18       Impact factor: 3.575

5.  Insulin- and leptin-regulated fatty acid uptake plays a key causal role in hepatic steatosis in mice with intact leptin signaling but not in ob/ob or db/db mice.

Authors:  Fengxia Ge; Shengli Zhou; Chunguang Hu; Harrison Lobdell; Paul D Berk
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-07-01       Impact factor: 4.052

Review 6.  Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance.

Authors:  Sung Hee Choi; Henry N Ginsberg
Journal:  Trends Endocrinol Metab       Date:  2011-05-26       Impact factor: 12.015

7.  Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone.

Authors:  Vernon W Dolinsky; Donna N Douglas; Richard Lehner; Dennis E Vance
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

8.  Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance.

Authors:  Erin E Mulvihill; Emma M Allister; Brian G Sutherland; Dawn E Telford; Cynthia G Sawyez; Jane Y Edwards; Janet M Markle; Robert A Hegele; Murray W Huff
Journal:  Diabetes       Date:  2009-07-10       Impact factor: 9.461

9.  CTRP12 inhibits triglyceride synthesis and export in hepatocytes by suppressing HNF-4α and DGAT2 expression.

Authors:  Stefanie Y Tan; Hannah C Little; Dylan C Sarver; Paul A Watkins; G William Wong
Journal:  FEBS Lett       Date:  2020-08-14       Impact factor: 4.124

Review 10.  Diabetic dyslipidaemia: from basic research to clinical practice.

Authors:  M-R Taskinen
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.